Literature DB >> 15028728

Arsenite sensitizes human melanomas to apoptosis via tumor necrosis factor alpha-mediated pathway.

Vladimir N Ivanov1, Tom K Hei.   

Abstract

Arsenic is a well established human carcinogen and is associated with a variety of cancers including those of the skin. Paradoxically, arsenic has also been used, amid at low doses, in the treatment of leukemia for over a century. Here we demonstrate that low to moderate concentrations of arsenite (2-10 microm) that has little or no effect on normal melanocytes may induce apoptosis of human melanomas including highly metastatic ones despite their low surface Fas levels. The two prerequisites that dictate apoptotic response of melanomas upon arsenite treatment are low nuclear NF-kappaB activity and an endogenous expression of tumor necrosis factor alpha. Under these conditions, melanoma cells acquired sensitivity to tumor necrosis factor alpha-mediated killing. On the other hand, signaling pathways including those of phosphatidylinositol 3-kinase-AKT, MEK-ERK, and JNK play a protective role against arsenite-induced oxidative stress and apoptosis in melanoma cells. Suppression of these pathways dramatically accelerates arsenite-induced apoptosis. Taken together, these data could provide potential approaches to sensitize melanomas to the cytotoxic effects of arsenite through modulating the signaling pathways.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15028728      PMCID: PMC4389905          DOI: 10.1074/jbc.M314131200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  78 in total

Review 1.  Mitochondrion as a novel target of anticancer chemotherapy.

Authors:  P Costantini; E Jacotot; D Decaudin; G Kroemer
Journal:  J Natl Cancer Inst       Date:  2000-07-05       Impact factor: 13.506

2.  NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling.

Authors:  S Kreuz; D Siegmund; P Scheurich; H Wajant
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

Review 3.  Novel therapies for multiple myeloma.

Authors:  Toshiaki Hayashi; Teru Hideshima; Kenneth C Anderson
Journal:  Br J Haematol       Date:  2003-01       Impact factor: 6.998

Review 4.  Targeting the PI3K-Akt pathway in human cancer: rationale and promise.

Authors:  Ji Luo; Brendan D Manning; Lewis C Cantley
Journal:  Cancer Cell       Date:  2003-10       Impact factor: 31.743

5.  Inhibition of NF-kappaB essentially contributes to arsenic-induced apoptosis.

Authors:  Stephan Mathas; Andreas Lietz; Martin Janz; Michael Hinz; Franziska Jundt; Claus Scheidereit; Kurt Bommert; Bernd Dorken
Journal:  Blood       Date:  2003-04-03       Impact factor: 22.113

6.  Inhibition of death receptor signals by cellular FLIP.

Authors:  M Irmler; M Thome; M Hahne; P Schneider; K Hofmann; V Steiner; J L Bodmer; M Schröter; K Burns; C Mattmann; D Rimoldi; L E French; J Tschopp
Journal:  Nature       Date:  1997-07-10       Impact factor: 49.962

7.  Coupling of a signal response domain in I kappa B alpha to multiple pathways for NF-kappa B activation.

Authors:  J A Brockman; D C Scherer; T A McKinsey; S M Hall; X Qi; W Y Lee; D W Ballard
Journal:  Mol Cell Biol       Date:  1995-05       Impact factor: 4.272

Review 8.  The paradox of arsenic: molecular mechanisms of cell transformation and chemotherapeutic effects.

Authors:  Ann M Bode; Zigang Dong
Journal:  Crit Rev Oncol Hematol       Date:  2002-04       Impact factor: 6.312

9.  Tumor promoter arsenite activates extracellular signal-regulated kinase through a signaling pathway mediated by epidermal growth factor receptor and Shc.

Authors:  W Chen; J L Martindale; N J Holbrook; Y Liu
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

10.  Nude rat models for human tumor metastasis to CNS. Procedures for intracarotid delivery of cancer cells and drugs.

Authors:  A T Myklebust; A Helseth; K Breistøl; W A Hall; O Fodstad
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

View more
  24 in total

1.  Arsenic trioxide and ascorbic acid demonstrate promising activity against primary human CLL cells in vitro.

Authors:  Sabyasachi Biswas; Xiaobin Zhao; Andrew P Mone; Xiaokui Mo; Melissa Vargo; David Jarjoura; John C Byrd; Natarajan Muthusamy
Journal:  Leuk Res       Date:  2010-02-19       Impact factor: 3.156

2.  Suppression of the proinflammatory response of metastatic melanoma cells increases TRAIL-induced apoptosis.

Authors:  Vladimir N Ivanov; Michael A Partridge; Sarah X L Huang; Tom K Hei
Journal:  J Cell Biochem       Date:  2011-02       Impact factor: 4.429

3.  Lymphokine-activated killer T-cell-originated protein kinase phosphorylation of histone H2AX prevents arsenite-induced apoptosis in RPMI7951 melanoma cells.

Authors:  Tatyana A Zykova; Feng Zhu; Chengrong Lu; LeeAnn Higgins; Yasuaki Tatsumi; Yasuhito Abe; Ann M Bode; Zigang Dong
Journal:  Clin Cancer Res       Date:  2006-12-01       Impact factor: 12.531

4.  Regulation of apoptosis in human melanoma and neuroblastoma cells by statins, sodium arsenite and TRAIL: a role of combined treatment versus monotherapy.

Authors:  Vladimir N Ivanov; Tom K Hei
Journal:  Apoptosis       Date:  2011-12       Impact factor: 4.677

5.  Sodium arsenite accelerates TRAIL-mediated apoptosis in melanoma cells through upregulation of TRAIL-R1/R2 surface levels and downregulation of cFLIP expression.

Authors:  Vladimir N Ivanov; Tom K Hei
Journal:  Exp Cell Res       Date:  2006-09-28       Impact factor: 3.905

6.  Radiosensitization of melanoma cells through combined inhibition of protein regulators of cell survival.

Authors:  Geoffrey E Johnson; Vladimir N Ivanov; Tom K Hei
Journal:  Apoptosis       Date:  2008-06       Impact factor: 4.677

7.  Tetramethylpyrazine (TMP) protects against sodium arsenite-induced nephrotoxicity by suppressing ROS production, mitochondrial dysfunction, pro-inflammatory signaling pathways and programed cell death.

Authors:  Xuezhong Gong; Vladimir N Ivanov; Mercy M Davidson; Tom K Hei
Journal:  Arch Toxicol       Date:  2014-06-25       Impact factor: 5.153

Review 8.  The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma.

Authors:  Subbarao V Madhunapantula; Gavin P Robertson
Journal:  Pigment Cell Melanoma Res       Date:  2009-05-28       Impact factor: 4.693

9.  Inhibition of ataxia telangiectasia mutated kinase activity enhances TRAIL-mediated apoptosis in human melanoma cells.

Authors:  Vladimir N Ivanov; Hongning Zhou; Michael A Partridge; Tom K Hei
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

10.  Dual treatment with COX-2 inhibitor and sodium arsenite leads to induction of surface Fas Ligand expression and Fas-Ligand-mediated apoptosis in human melanoma cells.

Authors:  Vladimir N Ivanov; Tom K Hei
Journal:  Exp Cell Res       Date:  2006-02-17       Impact factor: 3.905

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.